Attached files
| file | filename |
|---|---|
| EX-99 - EXHIBIT 99.1 - Insys Therapeutics, Inc. | ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 12, 2013
Insys Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
|
Delaware |
001-35902 |
51-0327886 |
|
(State of incorporation) |
(Commission File No.) |
(IRS Employer Identification No.) |
444 South Ellis Street
Chandler, Arizona 85224
(Address of principal executive offices and zip code)
Registrant’s telephone number, including area code: (602) 910-2617
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events.
On December 12, 2013, Insys Therapeutics, Inc. issued the press release attached hereto as Exhibit 99.1, which is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit No. |
|
Description |
|
|
| |
|
99.1 |
|
Press Release dated December 12, 2013 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Date: December 12, 2013 |
Insys Therapeutics, Inc. | |
|
|
|
|
|
|
By: |
/s/ Michael L. Babich |
|
|
|
Michael L. Babich |
|
|
|
President and Chief Executive Officer |